Company’s 36-month beta value is 1.66.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 4 as “overweight,” 11 as “hold,” and 2 as “sell.”
The public float for CRSP is 81.70M, and currently, short sellers hold a 22.17% ratio of that floaft. The average trading volume of CRSP on December 26, 2024 was 1.57M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRSP) stock’s latest price update
CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has soared by 1.14 in relation to previous closing price of 40.48. Nevertheless, the company has seen a loss of -8.27% in its stock price over the last five trading days. zacks.com reported 2024-12-23 that These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
CRSP’s Market Performance
CRSP’s stock has fallen by -8.27% in the past week, with a monthly drop of -14.49% and a quarterly drop of -10.84%. The volatility ratio for the week is 5.11% while the volatility levels for the last 30 days are 5.00% for CRISPR Therapeutics AG. The simple moving average for the past 20 days is -12.77% for CRSP’s stock, with a -23.42% simple moving average for the past 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Needham repeating the rating for CRSP by listing it as a “Buy.” The predicted price for CRSP in the upcoming period, according to Needham is $84 based on the research report published on August 06, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $90. The rating they have provided for CRSP stocks is “Buy” according to the report published on August 02nd, 2024.
CRSP Trading at -14.89% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.06% of loss for the given period.
Volatility was left at 5.00%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares sank -18.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.40% lower at present.
During the last 5 trading sessions, CRSP fell by -8.27%, which changed the moving average for the period of 200-days by -46.71% in comparison to the 20-day moving average, which settled at $46.93. In addition, CRISPR Therapeutics AG saw -34.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Kulkarni Samarth, who sale 15,000 shares at the price of $55.10 back on Dec 02 ’24. After this action, Kulkarni Samarth now owns 181,540 shares of CRISPR Therapeutics AG, valued at $826,564 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 30,000 shares at $55.62 during a trade that took place back on Nov 11 ’24, which means that Kulkarni Samarth is holding 196,540 shares at $1,668,678 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -1.65 for the present operating margin
- 0.31 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -1.19. The total capital return value is set at -0.15. Equity return is now at value -13.07, with -11.03 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -11.18.
Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 17.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.64.
Conclusion
In a nutshell, CRISPR Therapeutics AG (CRSP) has experienced a bad performance in recent times. The stock has received mixed “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
